Novartis studies show Onbrez® Breezhaler® plus tiotropium is more effective than tiotropium alone in treatment of COPD
Results of two Phase III studies show that once-daily Onbrez® Breezhaler® (indacaterol) plus tiotropium produced a significantly greater improvement in lung function than tiotropium alone in patients with chronic obstructive pulmonary disease (COPD)[1], supporting current treatment guidelines which recommend use of one or more bronchodilators for treating moderate-to-severe disease[2].
- (1888PressRelease) May 26, 2011 - The reported incidence of adverse events and serious adverse events was similar in both treatment groups[1].
"The internationally recognized GOLD guidelines state that combining bronchodilators with different modes of action may provide improved efficacy with no increase in side effects[2]", said the principal investigator Donald A. Mahler, MD, of the Dartmouth-Hitchcock Medical Center in Lebanon, New Hampshire, USA. "These are the first 12-week studies to report on the efficacy of two once-daily bronchodilators given concurrently, and the results confirm that the GOLD recommendation holds true for the use of indacaterol plus tiotropium."
The findings were presented today at the American Thoracic Society (ATS) congress in Denver, Colorado.
Onbrez Breezhaler is the only once-daily long-acting beta-2 agonist (LABA) approved in more than 50 countries, while tiotropium (Spiriva® HandiHaler®*) is a long-acting anti-muscarinic (LAMA), both indicated for the treatment of COPD. The two classes of medicines have different modes of action but both therapies are inhaled to provide bronchodilation, i.e. increased airflow into the patient's lungs.
The INTRUST 1 and 2 studies met their primary endpoints by demonstrating significant improvements in lung function of 130 and 120 mL respectively for Onbrez Breezhaler (150 mcg) plus tiotropium (18 mcg) compared to tiotropium alone after 12 weeks (both p
###
space
space
Satisfied Users & 
Approved Press Releases
Print
Email
Report Spam